DASAN Pharmaceutical stated that in response to the structural characteristics of the Chinese market, which relies heavily on imports and is primarily oriented towards raw materials, the company focused on actual raw material procurement and exchanges with existing partners. In particular, products such as Multi-Stra technology, liposome raw materials, and Bellapium SS garnered significant attention on-site, leading to intensive discussions with numerous buyers and suppliers.

DASAN Pharmaceutical's participation was not merely for promotion and exhibition; it was also aimed at strengthening its supply chain capabilities in China and other countries, in line with the accelerating policy of stabilizing supply chains, with the goal of establishing a solid foundation for supply chain circulation.